Viking Therapeutics, Inc. (VKTX)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $3.50B
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Latest financial period: June 30, 2026
Filed with the SEC: July 29, 2026
Estimated earnings date: October 28, 2026
Not currently ranked. Cannot calculate: sales growth, FCF yield
Profit Not currently ranked
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | | | | |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
